Iovance Biotherapeutics (NASDAQ:IOVA) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
This is a summary of current recommendations for Iovance Biotherapeutics and Genetic Technologies, as provided by MarketBeat.com.
Iovance Biotherapeutics presently has a consensus price target of $24.14, suggesting a potential upside of 122.93%. Given Iovance Biotherapeutics’ higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Genetic Technologies.
Valuation and Earnings
This table compares Iovance Biotherapeutics and Genetic Technologies’ top-line revenue, earnings per share (EPS) and valuation.
Genetic Technologies has higher revenue and earnings than Iovance Biotherapeutics.
Volatility and Risk
Iovance Biotherapeutics has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 3.85, indicating that its stock price is 285% more volatile than the S&P 500.
This table compares Iovance Biotherapeutics and Genetic Technologies’ net margins, return on equity and return on assets.
Insider & Institutional Ownership
96.9% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 3.9% of Genetic Technologies shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Genetic Technologies beats Iovance Biotherapeutics on 5 of the 9 factors compared between the two stocks.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Genetic Technologies Company Profile
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.